Crescent Biopharma Inc expected to post a loss of $1.76 a share - Earnings Preview
30/07/2025 12:09
Crescent Biopharma Inc CBIO.OQ CBIO.O is expected to show no change in quarterly revenue when it reports results on August 1 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Crescent Biopharma Inc is for a loss of $1.76 per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Crescent Biopharma Inc is $27.00, about 54.4% above its last closing price of $12.30 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -5.00 | -5.00 | -4.00 | Beat | 20 |
| 2025 | -11.20 | ||||
| -26.00 | | ||||
| Jun. 30 2024 | -16.19 | -16.75 | -16.00 | Beat | 4.5 |
| Mar. 31 2024 | -17.00 | -16.50 | -17.00 | Missed | -3 |
| Dec. 31 2023 | -15.00 | -15.25 | -14.00 | Beat | 8.2 |
| Sep. 30 2023 | -14.11 | -14.33 | -14.00 | Beat | 2.3 |
| Jun. 30 2023 | -17.81 | -18.33 | -13.00 | Beat | 29.1 |
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering